• 1
    Hosenpud JD, Bennett NE, Keck BM et al. The Registry of the International Society for Heart and Lung Transplantation: 18th Official Report. J Heart Lung Transplant 2001; 20: 805815.
  • 2
    Gao SZ, Schroeder JS, Alderman EL et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation 1989; 80 (Suppl. III): III-100III-105.
  • 3
    Costanzo M, Naftel D, Pritzker M et al. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of pre-operative donor and recipient risk factors. J Heart Lung Transplant 1998; 17: 744753.
  • 4
    Weis M, Von Scheidt W. Cardiac allograft vasculopathy. Circulation 1997; 96: 20692077.
  • 5
    Uretsky BF, Murali S, Reddy PS et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827834.
  • 6
    Olivari MT, Homans DC, Wilson RF et al. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy. Circulation 1989; 80 (Suppl. III): III-111III-115.
  • 7
    Zerbe T, Uretsky BF, Kormos R et al. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant 1992; 11: S104S110.
  • 8
    Radovancevic B, Poindexter S, Birovljev S et al. Risk factors of accelerated coronary artery disease in cardiac transplant recipients. Eur J CardioThorac Surg 1990; 4: 309313.
  • 9
    Schutz A, Kemkes BM, Kugler CH et al. The influence of rejection episodes on the development of coronary artery disease after heart transplantation. Eur J CardioThorac Surg 1990; 4: 300308.
  • 10
    Addonizio LJ, Hsu DT, Douglas JF et al. Decreasing incidence of coronary disease in pediatric transplant recipients using increased immunosuppression. Circulation 1993; 88: 224229.
  • 11
    Mehra MR, Ventura HO, Chambers R et al. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 1995; 26: 15371544.
  • 12
    Itescu S, Tung TCM, Burke EM et al. An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients. Lancet 1998; 352: 263270.
  • 13
    Gao SZ, Schroeder JS, Hunt SA et al. Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. J Heart Lung Transplant 1993; 12: 10291035.
  • 14
    Stovin PGI, Sharples LD, Schofield PM et al. Lack of association between endomyocardial evidence of rejection in the first six months and the later development of transplant-related coronary artery disease. J Heart Lung Transplant 1993; 12: 110116.
  • 15
    Rickenbacher PR, Pinto FJ, Lewis NP et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995; 92: 34453452.
  • 16
    Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336345.
  • 17
    Miller L, Kobashigawa J, Valantine H et al. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. J Heart Lung Transplant 1995; 14: 227234.
  • 18
    Lamich R, Ballester M, Martì V et al. Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. J Am Coll Cardiol 1998; 32: 413419.
  • 19
    Ratkovec RM, Wray RB, Renlund DG et al. Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation. J Thorac Cardiovasc Surg 1990; 100: 612.
  • 20
    Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992; 11: S124S132.
  • 21
    Caforio ALP, Belloni-Fortina A, Piaserico S et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102 (Suppl. III): III-222III-227.
  • 22
    Billingham ME, Cary NRB, Hammond EH et al. A working formulation for the standardisation of nomenclature in the diagnosis of heart and lung rejection: Heart rejection Study Group. J Heart Lung Transplant 1990; 8: 587593.
  • 23
    Milano A, Caforio AL, Livi U et al. Evolution of focal moderate (International Society for Heart and Lung Transplantation grade 2) rejection of the cardiac allograft. J Heart Lung Transplant 1996; 15: 456460.
  • 24
    Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III). JAMA 2001; 285: 24862497.
  • 25
    Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: update 2002. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002; 106: 388391.
  • 26
    The Report of the Sixth Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure. NIH Publication No. 98-4080. Bethesda , MD : National Institutes of Health , National High Blood Pressure Educational Program, 1997.
  • 27
    Davidson J, Wilkinson A, Dantal J et al. New onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75: SS3SS24.
  • 28
    Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621627.
  • 29
    Julius BK, Attenhofer Jost CH, Sutsch G et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation 2000; 69: 847853.
  • 30
    Rickenbacher PR, Pinto FJ, Chenzbraun A et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 1995; 25: 171177.
  • 31
    Hertz MI, Taylor DO, Trulock EP et al. The Registry of the International Society for Heart and Lung Transplantation: 19th Official Report-2002. J Heart Lung Transplant 2002; 21: 950970.
  • 32
    Lawless JF. Statistical Models and Methods for Lifetime Data. Chichester , UK : John Wiley and Sons, 1982.
  • 33
    Yamani MH, Tuzcu ME, Starling RC et al. Computerized scoring of histopathology for predicting coronary vasculopathy, validated by intravascular ultrasound. J Heart Lung Transplant 2002; 21: 850859.
  • 34
    Kirklin JK, Naftel DC, Bourge RC et al. Rejection after cardiac transplantation. A time–related risk factor analysis. Circulation 1991; 86 (Suppl. II): II-236II-241.
  • 35
    Costanzo-Nordin MR, Fisher SG, O'Sullivan JE et al. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis. J Heart Lung Transplant 1993; 12: 779789.
  • 36
    Valantine H. Neoral use in cardiac transplant recipient. Transplant Proc 2000; 32: 27S44S.